Tytuł pozycji:
Inhibition of Amyloid β-Induced Lipid Membrane Permeation and Amyloid β Aggregation by K162
- Tytuł:
-
Inhibition of Amyloid β-Induced Lipid Membrane Permeation and Amyloid β Aggregation by K162
- Autorzy:
-
Pieta, Piotr
Majewska, Marta
Pieta, Izabela S.
Mrdenowic, Dusan
Kutner, Robert
Nowakowski, Robert
Lipkowski, Jacek
Zarzycki, Piotr
- Współwytwórcy:
-
Department of Chemistry, University of Guelph, Canada
Faculty of Mathematics and Natural Sciences, School of Sciences, Cardinal Stefan Wyszynski University in Warsaw, Poland
Institute of Physical Chemistry, Polish Academy of Sciences
Energy Geosciences Division, Lawrence Berkeley National Laboratory, Berkeley,United States
- Data publikacji:
-
2021-12-03
- Wydawca:
-
American Chemical Society
- Słowa kluczowe:
-
amyloid β
Alzheimer’s disease
toxicity inhibition
amyloid β aggregation
membrane permeation
atomic force
- Język:
-
angielski
- ISBN, ISSN:
-
19487193
- Prawa:
-
http://creativecommons.org/licenses/by-nc/3.0/pl/
- Linki:
-
https://depot.ceon.pl/handle/123456789/21121  Link otwiera się w nowym oknie
- Dostawca treści:
-
Repozytorium Centrum Otwartej Nauki
-
Przejdź do źródła  Link otwiera się w nowym oknie
Alzheimer’s disease (AD) is characterized by progressive neurodegeneration associated with amyloid β (Aβ) peptide aggregation. The aggregation of Aβ monomers (AβMs) leads to the formation of Aβ oligomers (AβOs), the neurotoxic Aβ form, capable of permeating the cell membrane. Here, we investigated the effect of a fluorene-based active drug candidate, named K162, on both Aβ aggregation and AβO toxicity toward the bilayer lipid membrane (BLM). Electrochemical impedance spectroscopy (EIS), atomic force microscopy (AFM), and molecular dynamics (MD) were employed to show that K162 inhibits AβOs-induced BLM permeation, thus preserving BLM integrity. In the presence of K162, only shallow defects on the BLM surface were formed. Apparently, K162 modifies Aβ aggregation by bypassing the formation of toxic AβOs, and only nontoxic AβMs, dimers (AβDs), and fibrils (AβFs) are produced. Unlike other Aβ toxicity inhibitors, K162 preserves neurologically beneficial AβMs. This unique K162 inhibition mechanism provides an alternative AD therapeutic strategy that could be explored in the future.
This research was supported by receiving funding from the Polish National Science Centre, grant No. OPUS12 2016/23B/ST4/02791, awarded to P.P. The research activity of D.M. was supported by funds from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 711859 and by financial resources for science in the years 2017–2021 awarded by the Polish Ministry of Science and Higher Education for the implementation of an international cofinanced project. P.Z. acknowledges support from the US Department of Energy (DOE) Chemical Sciences, Geosciences, and Biosciences Division under Contract DE-AC02-05CH11231. The collaboration between the Polish Academy of Sciences and the Lawrence Berkeley National Laboratory was supported by grant NCN Sonata-Bis (DEC-2016/22/E/ST4/00446). J.L. acknowledges support of Natural Sciences and Engineering Research Council of Canada (NSERC) grant (RG-03958).